These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

726 related items for PubMed ID: 26891877

  • 1. Leukemogenic potency of the novel FLT3-N676K mutant.
    Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z.
    Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
    [Abstract] [Full Text] [Related]

  • 2. Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
    Opatz S, Polzer H, Herold T, Konstandin NP, Ksienzyk B, Zellmeier E, Vosberg S, Graf A, Krebs S, Blum H, Hopfner KP, Kakadia PM, Schneider S, Dufour A, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK, Greif PA.
    Blood; 2013 Sep 05; 122(10):1761-9. PubMed ID: 23878140
    [Abstract] [Full Text] [Related]

  • 3. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD.
    Blood; 2013 Nov 21; 122(22):3607-15. PubMed ID: 24046014
    [Abstract] [Full Text] [Related]

  • 4. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T.
    Leukemia; 2007 Mar 21; 21(3):403-10. PubMed ID: 17230226
    [Abstract] [Full Text] [Related]

  • 5. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.
    J Natl Cancer Inst; 2008 Feb 06; 100(3):184-98. PubMed ID: 18230792
    [Abstract] [Full Text] [Related]

  • 6. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.
    Hirade T, Abe M, Onishi C, Taketani T, Yamaguchi S, Fukuda S.
    Int J Hematol; 2016 Jan 06; 103(1):95-106. PubMed ID: 26590920
    [Abstract] [Full Text] [Related]

  • 7. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A, Heidel F, Fischer T, Rönnstrand L.
    Ann Hematol; 2018 May 06; 97(5):773-780. PubMed ID: 29372308
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
    Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, Kung AL, Armstrong SA.
    Leukemia; 2008 Jan 06; 22(1):66-77. PubMed ID: 17851551
    [Abstract] [Full Text] [Related]

  • 11. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P, Xiao X, Zhang Y, Zhang B, Li D, Liu M, Xie X, Liu C, Liu P, Ren R.
    J Hematol Oncol; 2021 Jul 03; 14(1):105. PubMed ID: 34217323
    [Abstract] [Full Text] [Related]

  • 12. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.
    Clin Cancer Res; 2014 May 01; 20(9):2363-74. PubMed ID: 24619500
    [Abstract] [Full Text] [Related]

  • 13. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, Fox CJ, Thompson CB, Cools J, Schwaller J.
    Cancer Res; 2006 Apr 01; 66(7):3828-35. PubMed ID: 16585210
    [Abstract] [Full Text] [Related]

  • 14. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.
    Kim HG, Kojima K, Swindle CS, Cotta CV, Huo Y, Reddy V, Klug CA.
    Blood; 2008 Feb 01; 111(3):1567-74. PubMed ID: 17967943
    [Abstract] [Full Text] [Related]

  • 15. Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.
    Thanasopoulou A, Tzankov A, Schwaller J.
    Haematologica; 2014 Sep 01; 99(9):1465-71. PubMed ID: 24951466
    [Abstract] [Full Text] [Related]

  • 16. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
    Nguyen B, Williams AB, Young DJ, Ma H, Li L, Levis M, Brown P, Small D.
    Oncotarget; 2017 Feb 14; 8(7):10931-10944. PubMed ID: 28077790
    [Abstract] [Full Text] [Related]

  • 17. The role of quizartinib in the treatment of acute myeloid leukemia.
    Ostronoff F, Estey E.
    Expert Opin Investig Drugs; 2013 Dec 14; 22(12):1659-69. PubMed ID: 24070241
    [Abstract] [Full Text] [Related]

  • 18. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
    Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel WE, Serve H.
    Cancer Res; 2005 Nov 01; 65(21):9643-50. PubMed ID: 16266983
    [Abstract] [Full Text] [Related]

  • 19. Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
    Nordigården A, Zetterblad J, Trinks C, Gréen H, Eliasson P, Druid P, Lotfi K, Rönnstrand L, Walz TM, Jönsson JI.
    Br J Haematol; 2011 Oct 01; 155(2):198-208. PubMed ID: 21848891
    [Abstract] [Full Text] [Related]

  • 20. FLT3-TKD mutation in childhood acute myeloid leukemia.
    Liang DC, Shih LY, Hung IJ, Yang CP, Chen SH, Jaing TH, Liu HC, Wang LY, Chang WH.
    Leukemia; 2003 May 01; 17(5):883-6. PubMed ID: 12750701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.